TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

ONeil Trader Investing Group Leader Follow Summary Shares of TG Therapeutics rose this week after buyout rumors surfaced. TG is a prime takeover target, fueled by Briumvi's growth and recent subcutaneous formulation de-risking. I see a potential acquisition premium of at least 45-50%, valuing TGTX at $73-76 per share, with strong standalone prospects regardless of M&A outcomes. Biogen and Incyte are the most plausible acquirers, but Sanofi, despite a larger market cap that does not fit into the rumored range, offers the strongest strategic fit for Briumvi. Even absent a buyout, TGTX is well-positioned for long-term value creation, with Briumvi expansion and pipeline diversification opportunities. Looking for more investing ideas like this one? Get them exclusively at Growth Stock Forum. Learn More » cagkansayin/iStock via Getty Images Shares of TG Therapeutics ( TGTX ) rose yesterday after a buyout rumor surfaced, saying that a larger biopharma company with a market cap in the $20-40 billion range is looking into acquiring TG. There are This article was written by ONeil Trader 9.65K Followers Follow ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on finding growth and biotech stocks with significant growth potential.He leads the investing group Growth Stock Forum which features: a model portfolio of 12-15 names updated regularly, a Top Picks list of up to 10 stocks that are expected to perform well in the current calendar year, Momentum Ideas that target both short-term and medium-term moves, and chat with community dialogue and for questions. Learn More. Analyst’s Disclosure: I/we have a beneficial long position in the shares of TGTX, GMAB, INSM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.